文献速递肿瘤 PET/CT核素与放射性配体治疗

FDG PET/CT 在前列腺癌患者管理中的作用

Role of FDG PET/CT in Management of Patients with Prostate Cancer.
PubMed 文献 · Semin Nucl Med · 2023-07-01

本文综述了[18F]FDG PET/CT 在前列腺癌管理中的角色:其在初始分期中价值有限,尤其在前列腺特异性膜抗原(PSMA)放射性示踪剂时代;在生化复发且 Grade group 4 或 5、PSA 升高时价值明显增加;双示踪剂分期可评估 PSMA 阴性/FDG 阳性不一致病灶;其真正价值在于晚期前列腺癌、PSMA 阴性病变、作为预后生物标志物及新型靶向诊疗药物领域。

要点

  • 前列腺内偶然发现的局灶性[18F]FDG 摄取并不少见,通常为良性。
  • [18F]FDG PET/CT 在前列腺癌初始分期中价值有限,尤其在 PSMA 放射性示踪剂时代。
  • FDG 与 PSMA 双示踪剂分期可评估 PSMA 阴性/FDG 阳性不一致病灶,提示可能从[177Lu]Lu-PSMA 治疗获益较少。

核心结论

  • [18F]FDG PET/CT 的真正价值在于晚期前列腺癌、PSMA 阴性病变、作为预后生物标志物以及新型靶向诊疗药物领域。
  • 识别 PSMA 阴性/FDG 阳性不一致病灶提示这些患者可能从[177Lu]Lu-PSMA 治疗获益较少。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 前列腺内偶然发现的局灶性[18F]FDG 摄取并不少见,通常为良性。
  • 增加对潜在前列腺癌担忧的影像特征包括腺体边缘附近外周带无钙化的局灶性摄取。
  • [18F]FDG PET/CT 在前列腺癌初始分期中价值有限,尤其在前列腺特异性膜抗原(PSMA)放射性示踪剂时代。
  • 在生化复发且存在 Grade group 4 或 5 及 PSA 水平升高时,[18F]FDG PET/CT 的价值明显增加。
  • FDG 与 PSMA 双示踪剂分期可显著提高疾病部位评估的准确性,[18F]FDG PET/CT 的加入允许评估 PSMA 阴性/FDG 阳性的不一致病变。

关键数值与推荐

  • 最大化[177Lu]Lu-PSMA 治疗获益依赖于所有疾病部位均有显著 PSMA 积聚。
  • 识别不一致病变提示这些患者可能从[177Lu]Lu-PSMA 治疗获益较少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate cancer is the second most common cancer in men worldwide. [18F]FDG PET/CT imaging, a well-known and effective technique for detecting malignancies, has not been considered a useful tool for prostate cancer imaging by many because of its perceived low [18F]FDG uptake. Incidentally detected focal [18F]FDG uptake in the prostate is not uncommon, and typically benign. Imaging features that would increase concern for an underlying prostatic carcinoma, include focal uptake in the periphery near the gland margin without calcifications. [18F]FDG PET/CT imaging provides little value in the initial staging of prostate cancer, particularly in the era of prostate specific membrane antigen (PSMA) radiotracer. In cases of biochemical recurrence, the value of [18F]FDG PET/CT increases notably when Grade group 4 or 5 and elevated PSA levels are present. Active research is underway for theranostic approaches to prostate cancer, including [177Lu]Lu-PSMA therapy. Dual tracer staging using FDG and PSMA imaging significantly enhances the accuracy of disease site assessment. Specifically, the addition of [18F]FDG PET/CT imaging allows for the evaluation of discordant disease (PSMA negative/FDG positive). The maximal benefit from [177Lu]Lu-PSMA therapy relies on significant PSMA accumulation across all disease sites, and the identification of discordant disease suggests that these patients may derive less benefit from the treatment. The genuine value of [18F]FDG PET/CT imaging lies in advanced prostate cancer, PSMA-negative disease, as a prognostic biomarker, and the realm of new targeted theranostic agents.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sutherland DEK, Azad AA, Murphy DG, et al. Role of FDG PET/CT in Management of Patients with Prostate Cancer. Semin Nucl Med. 2023. PMID: 37400321. doi:10.1053/j.semnuclmed.2023.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。